The Russian market of anticoagulants has been expanded with European rivaroxan produced by Egis Pharmaceuticals PLC (Hungary). The product from the class of direct oral anticoagulants combines European manufacturing standards and practical benefits for patients. With a convenient one-pill-per-day regime and affordability, this product opens up new possibilities in the prevention of thrombosis, significantly increasing the availability of modern anticoagulation therapy and contributing to improved patient commitment to long-term treatment.

Egis Pharmaceuticals Plc. applied for the prestigious Top Employer Hungary certification for the first time and successfully joined the ranks of companies recognized for their outstanding employer practices on an international level.

On February 26, 2025, the Parents´ Choice Association of Consumers and Manufacturers of Children´s Products awarded the winners of the Parents´ Choice 2025 award! According to the results of the vote of the national jury in the nomination ˝Women´s Health˝, the Vagilak Proledi brand for women´s intimate health (Egis became the winner.